Fenofibrate Oral Capsule 150Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Fenofibrate: Oral capsule (150mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_10772.JPG
Lipofen 150mg Cap
Kowa Pharmaceuticals America (formerly Proethic Pharmaceuticals Inc)
Pill Identification: G248 150 
Drug Image file DrugItem_10152.JPG
Lipofen 150mg Cap
Kowa Pharmaceuticals America (formerly Proethic Pharmaceuticals Inc)
Pill Identification: G248 150 
Drug Image file DrugItem_18197.JPG
Fenofibrate 150mg Capsule
H2-Pharma, LLC
Pill Identification: G248 150 

What is this Medicine?

FENOFIBRATE (fen oh FYE brate) capsules can help lower blood fats and cholesterol for people who are at risk of getting inflammation of the pancreas (pancreatitis) from having very high amounts of fats in their blood. This medicine is only for patients whose blood fats are not controlled by diet.

In-Depth Information

Fenofibrate 150mg Capsule

NDC: 612690212
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Hypercholesterolemia, Hypertriglyceridemia

Storage Information
Store at room temperature (between 59 to 86 degrees F)
Protect from light
Protect from moisture
Fenofibrate 150mg Capsule
Drug Image file DrugItem_18197.JPG
H2-Pharma, LLC
Pill Identification: G248 150 
Shape: capsule
Color: white

Reported Side Effects for Fenofibrate 150mg Capsule

Blood Clot Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Blood Clot In Lung Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Hives Incidence:
1.1%*
Severity: MILD
Onset: RAPID
Skin Rash Incidence:
1.4%*
Severity: MILD
Onset: EARLY
Constipation Incidence:
2.1%*
Severity: MODERATE
Onset: DELAYED
Weakness Incidence:
2.1%*
Severity: MILD
Onset: DELAYED
Rhinitis Incidence:
2.3%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
2.3%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
2.3%*
Severity: MILD
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
3.0-13.0%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
3.2%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
3.4%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
4.6%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Fenofibrate

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.